Glecirasib, a highly selective, covalent oral KRAS G12C inhibitor, has demonstrated promising clinical activity in NSCLC and CRC; however, the efficacy and safety of glecirasib are unknown in PDAC and other solid tum...
a KRAS G12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors. Mol Cancer Ther. 2021;20(suppl 12):P05-01.
a KRAS G12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors. Mol Cancer Ther. 2021;20(suppl 12):P05-01.
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-...
USAofsotorasibinMay2021.Sotorasib,aKRASG12C inhibitor,isindicatedforthetreatmentofadultswith KRASG12C-mutatedlocallyadvancedormetastatic non-smallcelllungcancer(NSCLC)whohavereceived atleastonepriorsystemictherapy.Theapprovalwas basedondatafromtheCodeBreaK100Phase1/2trial ...
Sotorasib使肿瘤显著缩小,对1例PS差(与肿瘤快速生长和肿瘤诱发的DIC相关)的KRAS G12C突变患者有充分疗效。虽然Sotorasib治疗后PFS仅为4个月,但PS评分改善对于后续治疗具有显著意义。 参考文献 上下滑动查看更多内容 1. Canon J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity...
Impact of trial eligibility criteria on enrollment to KRASG12Cinhibitor trials in patients with non-small cell lung cancer.doi:10.1200/JCO.2024.42.16_suppl.110125311012#Background:Clinical trials of novel therapies should enroll a population that reflects patients (pts) who might receive the drug...
2月20日,Adagrasib的补充新药申请(sNDA)获FDA受理并将其纳入优先审评。用于联合西妥昔单抗治疗既往接受过治疗的KRASG12C突变型局部晚期或转移性结直肠癌(CRC)患者。 值得注意的是:目前上市的这两款KRAS抑制剂均未在在大陆上市,需要在海外或者香港、海南等地购买。
[8] Daniel S. Tan et al. Abstract CT033 – KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors. [9] Jian Li et al. A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in ad...
[1]Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;10.1056/NEJMoa2103695. doi:10.1056/NEJMoa2103695 [2] Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. ...